Drugs & Targets FDA grants accelerated approval to Iclusig + chemotherapy for newly diagnosed Ph+ ALL March 22, 2024Vol.50 No.12
Drugs & Targets FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products March 22, 2024Vol.50 No.12
Conversation with The Cancer LetterRegulatory News FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLCPooled analysis finds correlations between early endpoints and OS in ICI trials March 15, 2024Vol.50 No.11By Matthew Bin Han Ong and Paul Goldberg
Regulatory News ODAC gives thumbs-up to imetelstat for MDS, upholding the value of transfusion independence March 15, 2024Vol.50 No.11By Jacquelyn Cobb and Paul Goldberg
Drugs & Targets FDA approves Breyanzi CAR T-cell therapy in adults with R/R/ CLL or SLL March 15, 2024Vol.50 No.11
Drugs & Targets FDA approves Tevimbra in advanced or metastatic esophageal squamous cell carcinoma indication March 15, 2024Vol.50 No.11
Drugs & Targets FDA approves Rybrevant for first-line treatment of EGFR-m NSCLC March 08, 2024Vol.50 No.10
Drugs & Targets FDA approves Opdivo + cisplatin + gemcitabine for unresectable or metastatic urothelial carcinoma March 08, 2024Vol.50 No.10
Drugs & Targets FDA grants accelerated approval to Brukinsa for R/R follicular lymphoma March 08, 2024Vol.50 No.10
